ClinConnect ClinConnect Logo
Search / Trial NCT01679314

Study to Compare (COPD) Assessment Test in COPD Stage III and IV in a Prophylactic Treatment

Launched by ELECTROCORE INC · Aug 31, 2012

Trial Information

Current as of July 08, 2025

Completed

Keywords

Copd Vagus Nerve Stimulation Vagal Nerve Stimulation N Vns Vns Non Invasive Gammacore

ClinConnect Summary

PERFORMANCE AND SAFETY VARIABLES:

The primary efficacy endpoint for this study is the total Chronic obstructive pulmonary disease (COPD) Assessment Test (CAT) score change from baseline to the 8 week follow-up period comparing the two device groups.

Secondary efficacy endpoints will be the mean difference from baseline to the 8 week follow-up for the following assessments: Medical Research Council (MRC) dyspnoea scale, 6 minutes walking test and Forced Expiratory Volume in one second (FEV1)

Safety Variables:

Each subject will be assessed throughout the study for Adverse Events and at th...

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Age 40-75 years
  • Diagnosed Chronic obstructive pulmonary disease(COPD) stage III and IV according to Global Initiative for chronic obstructive lung disease (GOLD) guideline
  • Forced expiratory volume in one second (FEV 1) \< 50%
  • Forced expiratory volume in one second (FEV1/Forced expiratory vital capacity (FVC) \< 70%
  • Signed informed consent form
  • Exclusion Criteria:
  • Participation in other clinical trials (drug or medical device) 30 days prior to start of this study
  • Subject is unable to comply with the procedures if the protocol for the study or any other reason judged by the Investigator that could interfere with the study assessment or follow-up
  • Has an abscess or other infection or lesion (including lymphadenopathy) at the AlphaCore® treatment site.
  • Is currently implanted with an electrical and/or neurostimulator device, including but not limited to cardiac pacemaker, defibrillator, vagal neurostimulator, deep brain stimulator, spinal stimulator, bone growth stimulator, or cochlear implant.
  • Has a history of carotid endarterectomy or vascular neck surgery on the right side.
  • Right side or bilateral vagotomy
  • Has a recent or repeated history of syncope.
  • Has a recent or repeated history of seizures.
  • Pregnant or breast feeding women

About Electrocore Inc

Electrocore Inc. is a pioneering medical technology company focused on developing non-invasive neuromodulation therapies for the treatment of various chronic conditions. With a commitment to advancing healthcare through innovative solutions, Electrocore specializes in transcutaneous vagus nerve stimulation (tVNS) technology, which aims to improve patient outcomes in areas such as migraine, cluster headache, and other neurological disorders. The company emphasizes rigorous clinical research and collaboration with healthcare professionals to ensure the efficacy and safety of its products, ultimately enhancing the quality of life for patients worldwide.

Locations

Schwedt, Oder, Germany

Patients applied

0 patients applied

Trial Officials

Matthias John, MD

Principal Investigator

Praxis für Pneumologie am Asklepios Klinikum Uckermark

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials